Developing solutions to improve post-cataract surgery vision.
OnPoint Vision™ designs, develops and manufactures intraocular lenses intended to correct residual refractive error in patients who have already undergone cataract surgery as well as employ a strong interest in the treatment of patients who have experienced visual decline due to age-related retinal pathologies.
Our mission is to provide a highly differentiated minimally-invasive surgical solution designed to customize the visual outcome of the pseudophakic eye.
OnPoint Vision Sees Clear Road Ahead
The Food and Drug Administration initially accepted Kevin Cady’s proposal for an implantable lens to correct vision after cataract surgery. Then the FDA switched course by asking Cady to consider a different unmet need—patients suffering from macular degeneration, with vision 20/80 or worse.
“I thought this wouldn’t help us,” Cady recalled. “But they did us a favor. They opened our eyes— there might be another population that this lens application can serve.”
Key Opinion Leaders Praise AccuraSee IOPCL Presentation at AECOS
OnPoint Vision president Kevin Cady was honored to present at the AECOS 2022 summer symposium.
The AccuraSee IOPCL presentation scored high among the physician attendees.